Drug Type AAV based gene therapy |
Synonyms Neurotrophin 3 gene therapy, NT 3 gene therapy |
Target |
Action- |
Mechanism Neurotrophin-3 expression stimulants, Gene transference |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseSuspendedPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Charcot-Marie-Tooth Disease, Type Ia | Phase 2 | United States | 01 Apr 2025 |